94 related articles for article (PubMed ID: 15862961)
1. Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production.
Andrews WJ; Winnett G; Rehman F; Shanmugasundaram P; Hagen Dv; Schrey MP
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):159-65. PubMed ID: 15862961
[TBL] [Abstract][Full Text] [Related]
2. Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity.
Rehman F; Shanmugasundaram P; Schrey MP
Br J Cancer; 2004 Nov; 91(10):1821-8. PubMed ID: 15505623
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: potential implications for breast cancer therapy.
Winnett G; van Hagen D; Schrey M
Int J Cancer; 2003 Feb; 103(5):600-5. PubMed ID: 12494466
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.
Ciolino HP; Wang TT; Sathyamoorthy N
Br J Cancer; 2000 Aug; 83(3):333-7. PubMed ID: 10917548
[TBL] [Abstract][Full Text] [Related]
5. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase.
Wang H; Maurer BJ; Reynolds CP; Cabot MC
Cancer Res; 2001 Jul; 61(13):5102-5. PubMed ID: 11431347
[TBL] [Abstract][Full Text] [Related]
6. PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation.
Appierto V; Tiberio P; Villani MG; Cavadini E; Formelli F
Carcinogenesis; 2009 May; 30(5):824-31. PubMed ID: 19325135
[TBL] [Abstract][Full Text] [Related]
7. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
8. Involvement of Rac in fenretinide-induced apoptosis.
Kadara H; Tahara E; Kim HJ; Lotan D; Myers J; Lotan R
Cancer Res; 2008 Jun; 68(11):4416-23. PubMed ID: 18519704
[TBL] [Abstract][Full Text] [Related]
9. Enhanced killing of SCC17B human head and neck squamous cell carcinoma cells after photodynamic therapy plus fenretinide via the de novo sphingolipid biosynthesis pathway and apoptosis.
Boppana NB; Stochaj U; Kodiha M; Bielawska A; Bielawski J; Pierce JS; Korbelik M; Separovic D
Int J Oncol; 2015 May; 46(5):2003-10. PubMed ID: 25739041
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts.
Zou C; Brewer M; Cao X; Zang R; Lin J; Deng Y; Li C
Gynecol Oncol; 2007 Dec; 107(3):441-9. PubMed ID: 17854871
[TBL] [Abstract][Full Text] [Related]
11. Ceramide synthesis and metabolism as a target for cancer therapy.
Reynolds CP; Maurer BJ; Kolesnick RN
Cancer Lett; 2004 Apr; 206(2):169-80. PubMed ID: 15013522
[TBL] [Abstract][Full Text] [Related]
12. Protection of RPE cells from oxidative injury by 15-deoxy-delta12,14-prostaglandin J2 by augmenting GSH and activating MAPK.
Qin S; McLaughlin AP; De Vries GW
Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):5098-105. PubMed ID: 17065531
[TBL] [Abstract][Full Text] [Related]
13. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.
Ferrari N; Pfeffer U; Dell'Eva R; Ambrosini C; Noonan DM; Albini A
Clin Cancer Res; 2005 Jun; 11(12):4610-9. PubMed ID: 15958647
[TBL] [Abstract][Full Text] [Related]
14. Ceramide metabolite, not intact ceramide molecule, may be responsible for cellular toxicity.
Tserng KY; Griffin RL
Biochem J; 2004 Jun; 380(Pt 3):715-22. PubMed ID: 14998372
[TBL] [Abstract][Full Text] [Related]
15. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.
O'Donnell PH; Guo WX; Reynolds CP; Maurer BJ
Leukemia; 2002 May; 16(5):902-10. PubMed ID: 11986953
[TBL] [Abstract][Full Text] [Related]
16. Ceramide, a target for antiretroviral therapy.
Finnegan CM; Rawat SS; Puri A; Wang JM; Ruscetti FW; Blumenthal R
Proc Natl Acad Sci U S A; 2004 Oct; 101(43):15452-7. PubMed ID: 15489273
[TBL] [Abstract][Full Text] [Related]
17. 4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells.
Su B; Mershon SM; Stonerock LA; Curley RW; Brueggemeier RW
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):40-6. PubMed ID: 18248980
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide.
Vilela RM; Lands LC; Meehan B; Kubow S
Int Immunopharmacol; 2006 Nov; 6(11):1651-64. PubMed ID: 16979119
[TBL] [Abstract][Full Text] [Related]
19. Human T-cell lymphotropic virus type I-transformed T-cells have a partial defect in ceramide synthesis in response to N-(4-hydroxyphenyl)retinamide.
Darwiche N; Abou-Lteif G; Najdi T; Kozhaya L; Tayoun AA; Bazarbachi A; Dbaibo GS
Biochem J; 2005 Nov; 392(Pt 1):231-9. PubMed ID: 16086670
[TBL] [Abstract][Full Text] [Related]
20. ROS mediates 4HPR-induced posttranscriptional expression of the Gadd153 gene.
Lai WL; Wong NS
Free Radic Biol Med; 2005 Jun; 38(12):1585-93. PubMed ID: 15917187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
